Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT02588612 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: letetresgene autoleucel (GSK3377794)
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

GlaxoSmithKline